Alembic Pharmaceuticals has received U.S. Food and Drug Administration final approval for its abbreviated new drug application for Carbidopa, Levodopa and Entacapone Tablets in different strengths.

Alembic Pharma (ALPM) exhibited in-line revenue with a slight miss on EBITDA/PAT for the quarter. While ex-US export growth was strong for the quarter, it was offset by moderate YoY growth in domestic ...